{"id":915325,"date":"2025-12-02T12:12:25","date_gmt":"2025-12-02T17:12:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-announces-world-health-organization-approval-of-olastrocel-as-inn-for-lead-allogeneic-cell-therapy-celz-201\/"},"modified":"2025-12-02T12:12:25","modified_gmt":"2025-12-02T17:12:25","slug":"creative-medical-technology-holdings-announces-world-health-organization-approval-of-olastrocel-as-inn-for-lead-allogeneic-cell-therapy-celz-201","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-announces-world-health-organization-approval-of-olastrocel-as-inn-for-lead-allogeneic-cell-therapy-celz-201\/","title":{"rendered":"Creative Medical Technology Holdings Announces World Health Organization Approval of \u201colastrocel\u201d as INN for Lead Allogeneic Cell Therapy CELZ-201"},"content":{"rendered":"

\nGlobal assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel\u2019s advancement across large unmet-need global markets
\n<\/h2>\n
\n

PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)<\/strong> (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced that the World Health Organization (WHO) has approved \u201colastrocel\u201d as the International Non-Proprietary Name (INN) for the active cellular substance in CELZ-201, the Company\u2019s lead allogeneic cell therapy also known as AlloStem\u00ae.<\/p>\n

The INN is the globally standardized, unique scientific name used by regulators, clinicians, researchers, and global markets to identify a therapeutic substance throughout its development and commercialization lifecycle. This assignment is a key global milestone that typically occurs as a program advances into later regulatory stages and requires unified international identification.<\/p>\n

\u201cSecuring the name \u2018olastrocel\u2019 marks an important advancement for our program,\u201d said Timothy Warbington, President and CEO of Creative Medical. \u201cA WHO-recognized INN is foundational for global development, medical adoption, and long-term scalability. It provides a cohesive scientific identity for the asset as we continue to execute on our clinical strategy in large markets with significant unmet medical needs.\u201d<\/p>\n

Mr. Warbington continued, \u201cFrom an investor perspective, this milestone reflects disciplined progress and strengthens the foundation for the olastrocel platform. Combined with our FDA Fast Track designation in degenerative disc disease, we believe the program is well-positioned as we move toward additional clinical catalysts ahead. The therapeutic areas we are targeting – chronic lower back pain, diabetes, and immune-mediated conditions – represent multi-billion-dollar opportunities where innovation is urgently needed.<\/p>\n

\n \u201c<\/em>Our team remains focused, data-driven, and committed to advancing olastrocel through the next phases of development,\u201d he added. \u201cThis is an exciting moment for Creative Medical and our shareholders as we continue building a differentiated, next-generation cell therapy franchise.\u201d<\/p>\n

\n Why the INN Matters<\/strong>
\n
The assignment of \u201colastrocel\u201d provides:<\/p>\n